Casey Morris, MD
Critical Care Medicine · Savannah, GANPI 1235548140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$864
- Sanofi$529
- Regeneron Healthcare Solutions, Inc.$506
- AstraZeneca$466
- Insmed, Inc.$410
- Boehringer Ingelheim$334
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,34798%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 58 | $864 |
| Sanofi | 16 | $529 |
| Regeneron Healthcare Solutions, Inc. | 18 | $506 |
| AstraZeneca | 22 | $466 |
| Insmed, Inc. | 29 | $410 |
| Boehringer Ingelheim | 16 | $334 |
| Grifols USA, LLC | 10 | $250 |
| Actelion Pharmaceuticals US, Inc. | 10 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $194 |
| United Therapeutics Corporation | 9 | $190 |
| Mylan Specialty L.p. | 7 | $141 |
| Philips North America LLC | 6 | $135 |
| Jazz Pharmaceuticals Inc. | 5 | $131 |
| Amgen | 7 | $130 |
| Baxter Healthcare | 5 | $119 |
| Axsome Therapeutics, Inc. | 4 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Mallinckrodt Hospital Products Inc. | 4 | $94 |
| Pulmonx Corporation | 2 | $85 |
| Verona Pharma, Inc. | 3 | $77 |
| Electromed, Inc. | 8 | $72 |
| ANI Pharmaceuticals, Inc. | 3 | $59 |
| Harmony Biosciences LLC | 2 | $56 |
| Merck | 3 | $54 |
| Pfizer | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$5,445 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $71,263 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,221 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $16,966 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $13,600 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,865 |
| DuleraMometasone/Formoterol | 13 | $4,320 |
| Roflumilast | 12 | $1,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $832 |
| Azelastine Hcl | 24 | $569 |
| Azithromycin | 39 | $517 |
| Montelukast Sodium | 40 | $346 |
| Ipratropium Bromide | 12 | $292 |
| Prednisone | 48 | $233 |
| Methylprednisolone | 22 | $201 |
| Fluticasone Propionate | 15 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $864 | $101,829155 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $466 | $31,08656 claims |
| MerckDulera | $54 | $4,32013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Savannah
- Craig SchuringSavannah$12K
- Kathia Ortiz-CantilloSavannah$8K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
- Matthew SchmittAtlanta$32K
- Prasad GarimellaBraselton$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.